- Company
- Samsung Epis, made a surplus of ₩122.5 billion
- by Chon, Seung-Hyun Apr 1, 2020 06:16am
- Samsung Bioepis has made a surplus for the first time since its inception. It has been in deficit every year since its inception in 2012, but it recorded operating profit of &8361;122.5 billion due to the growth of biosimilars in overseas markets. Sales also grew more than twice that of the previous year. According to Samsung Bioepis' audit
- Company
- Xeljanz to be used with caution in thrombosis patients
- by Nho, Byung Chul Mar 30, 2020 06:18am
- Among the indications for Pfizer's JAK inhibitor Xeljanz (Tofacitinib citrate), the standard for 10 mg high dose prescription of ulcerative colitis has changed. Pfizer recently changed the permission, and added that patients with risk factors for thrombosis should avoid using this drug and patients with signs·symptoms of thrombosis should
- Company
- SK nabs approval for cilostazol-ginko combination SR drug
- by Lee, Seok-Jun Mar 29, 2020 11:19pm
- On Mar. 25, SK Chemicals has announced the Korean health authority has approved sustained release tablet version of antiplatelet drug Renexin. Renexin is a combination drug consisting of antiplatelet agent cilostazol (200 mg) and ginko biloba extract (160 mg). The combination drug, with cilostazol and ginko biloba extract inhibiting p
- Company
- Lipitor and Vytorin to be priced lower than generic?
- by Eo, Yun-Ho Mar 29, 2020 11:18pm
- An odd phenomenon of the original’s pricing dipping down to 85 percent of the lowest generic pricing may actually happen in Korea. The stepped drug pricing system coming in effect from July prices same-substance drugs under differentiated pricing depending on drugs meeting two qualifying standards. But from 21st same-substance drug, the
- Company
- Novartis vs. Hanmi: Galvus generic to ignite legal dispute
- by Eo, Yun-Ho Mar 26, 2020 06:12am
- A conflict between Novartis and Hanmi Pharmaceutical is expected to deepen over the generic of the DDP-4 inhibitor Galvus. Novartis Korea is apparently preparing legal actions against Korean pharmaceutical companies attempting to evade patent infringement on Galvus (vildagliptin) by excluding one indication. The legal dispute over the
- Company
- FDA approves Phase III Actemra COVID-19 trial
- by An, Kyung-Jin Mar 26, 2020 06:11am
- A late-phase clinical trial in patients with severe case of the 2019 novel coronavirus (COVID-19) would be conducted with Actemra, solely distributed by JW Pharmaceutical in Korea. Roche Group’s Genentech has announced on Mar. 23 the U.S. Food and Drug Administration (FDA) has approved Actemra’s (tocilizumab) Phase III clinical trial
- Company
- Celltrion, clinical trial in COVID-19 in July
- by Lee, Seok-Jun Mar 26, 2020 06:10am
- Chairman Jeong-jin Seo of Celltrion said on the 23rd, "This July, human clinical trials will be started for the development of COVID-19 treatments". He added, "It is possible to develop a therapeutic antibody for 1 million people per month after human administration". Chairman Seo shared this business plan through an online press conferenc
- Company
- General hospitals codes in new antiosteoporosis Evenity
- by Eo, Yun-Ho Mar 25, 2020 06:03am
- Korean general hospitals are adding osteoporosis treatment Evenity in the prescription code. The pharmaceutical industry sources report Amgen’s Evenity (romosozumab) has been passed by drug committees at the Big Five general hospitals like Samsung Medical Center, Seoul Asan Medical Center and Severance Hospital, as well as Gangnam Sever
- Company
- Balloon effect from impurity measures?
- by Chon, Seung-Hyun Mar 25, 2020 06:03am
- Recently, the number of new anti-ulcer drugs that enter the market is rapidly increasing. As the alternative drug market expanded after the Ranitidine’s withdrawal due to excessive detection of impurities in September last year, pharmaceuticals are also actively targeting the generic market. In addition to H2 receptor antagonists such as Fa
- Company
- Jina Lee at Bayer stepped up as CEO of Thai Corporation
- by Eo, Yun-Ho Mar 24, 2020 05:20am
- Jina Lee, Health BU Head at Bayer, will be represented as the CEO of Thai corporation. Bayer Korea recently announced in its internal announcement that Jina Lee will be appointed as the CDH (Country Division Head) of the Thai Pharmaceutical Division. However, due to the aftermath of COVID-19, the exact departure schedule and the like have
